Evidence map›Paper›PMID 42061821›Full record

ArticleAntiviral research2026

Efficacy of an Fc-silent antibody targeting the apical domain of human transferrin receptor 1 in transgenic mouse models of Junín virus infection.

Minghao Li, Samantha R Wasson, Tracy R Daniels-Wells, Jonna B Westover, Pierre V Candelaria, Kevin W Bailey, Manuel L Penichet, Brian B Gowen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Minghao LiDepartment of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA; Institute for Antiviral Research, Utah State University, Logan, UT, USA.
Samantha R WassonDepartment of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA; Institute for Antiviral Research, Utah State University, Logan, UT, USA.
Tracy R Daniels-WellsDivision of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.
Jonna B WestoverDepartment of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA; Institute for Antiviral Research, Utah State University, Logan, UT, USA.
Pierre V CandelariaDivision of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.
Kevin W BaileyDepartment of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA; Institute for Antiviral Research, Utah State University, Logan, UT, USA.
Manuel L PenichetDivision of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA; Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; UCLA Molecular Biology Institute, Los Angeles, CA, USA; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA; UCLA AIDS Institute, Los Angeles, CA, USA. Electronic address: penichet@mednet.ucla.edu.
Brian B GowenDepartment of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA; Institute for Antiviral Research, Utah State University, Logan, UT, USA. Electronic address: brian.gowen@usu.edu.

Funding

Antibody-based therapeutic strategy for New World mammarenavirus hemorrhagic feverR01AI173769 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Brian B. Gowen, MANUEL L PENICHET · 2023 to 2026
$3.0M
NIAID NIH HHS R01 AI173769
6 · The paper itself

Abstract

Several New World mammarenaviruses (NWMs), including Junín virus (JUNV), can cause a severe, potentially fatal hemorrhagic fever (HF) syndrome. In the absence of FDA-approved vaccines or antivirals, there is an urgent need to develop broadly active countermeasures against these viral infections. Cellular entry by all pathogenic NWMs is mediated by transferrin receptor 1 (TfR1). Here, we report on the pharmacokinetics (PK) and antiviral activity of a mouse/human chimeric antibody, targeting the apical domain of human TfR1 and lacking effector functions (ch128.1/IgG1 Fc-silent) in two transgenic mouse models of JUNV infection. Assessment of tolerability and PK in human TfR1 knock-in/mouse TfR1 knock-out mice (huTfR1 Tg mice) demonstrated that ch128.1/IgG1 Fc-silent (FcS) was well-tolerated at doses up to 800 μg, and that once-daily dosing may be the most effective regimen for achieving optimal therapeutic benefit. Prophylactic and post-infection intervention efficacy studies employing once-daily antibody treatments in huTfR1 Tg mice challenged with JUNV revealed significant protection against mortality, even when treatment was delayed until 5 days post-infection. In mice with TfR1 containing only the apical domain of the human receptor (huApTfR1 Tg mice), the ch128.1/IgG1 FcS treatment trended toward increased survival and significantly reduced weight loss following JUNV challenge. The antibody treatments also significantly decreased infectious JUNV titers in target organs (liver and spleen) in the more physiologically relevant huApTfR1 Tg mouse model. Taken together, effective treatment of advanced JUNV infection in two transgenic mouse models with ch128.1/IgG1 FcS antibody supports the development of a humanized version of this antibody for clinical application.

Indexed as

Antibodies, ViralAntigens, CDAntiviral AgentsArenaviridae InfectionsJunin virusReceptors, TransferrinAnimalsDisease Models, AnimalFemaleHumansImmunoglobulin GMiceMice, KnockoutMice, TransgenicAntibodies, ViralAntigens, CDAntiviral AgentsCD71 antigenImmunoglobulin GReceptors, TransferrinAnimal modelAntiviralJunín virusMammarenavirusTherapeutic antibody

Identifiers

PMID42061821
PMCPMC13245545

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.